AZN has been the topic of a number of other reports. Citigroup Inc. reaffirmed a buy rating on shares of Astrazeneca PLC in a research note on Wednesday, July 27th. Bank of America Corp. set a $41.40 price target on shares of Astrazeneca PLC and gave the company a buy rating in a research note on Thursday, September 8th. Piper Jaffray Cos. assumed coverage on shares of Astrazeneca PLC in a research note on Friday, September 23rd. They issued an overweight rating on the stock. TheStreet raised shares of Astrazeneca PLC from a hold rating to a buy rating in a research note on Friday, July 22nd. Finally, BNP Paribas lowered shares of Astrazeneca PLC from an outperform rating to a neutral rating in a research note on Tuesday, September 13th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and an average target price of $37.44.
Astrazeneca PLC (NYSE:AZN) opened at 32.29 on Friday. Astrazeneca PLC has a 12 month low of $26.97 and a 12 month high of $35.04. The firm’s 50 day moving average price is $33.23 and its 200 day moving average price is $30.79. The stock has a market cap of $81.69 billion, a price-to-earnings ratio of 36.90 and a beta of 0.75.
Astrazeneca PLC (NYSE:AZN) last posted its earnings results on Thursday, July 28th. The company reported $0.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.76 by $0.07. Astrazeneca PLC had a net margin of 9.23% and a return on equity of 28.02%. The business had revenue of $5.60 billion for the quarter, compared to analyst estimates of $5.56 billion. During the same period in the prior year, the company posted $1.21 EPS. The company’s revenue for the quarter was down 4.0% on a year-over-year basis. On average, equities research analysts predict that Astrazeneca PLC will post $2.97 EPS for the current fiscal year.
The firm also recently declared a dividend, which was paid on Monday, September 12th. Shareholders of record on Friday, August 12th were given a $0.44 dividend. The ex-dividend date was Wednesday, August 10th. Astrazeneca PLC’s dividend payout ratio is presently 78.29%.
A number of institutional investors have recently modified their holdings of the stock. TIAA CREF Investment Management LLC boosted its position in shares of Astrazeneca PLC by 45.2% in the first quarter. TIAA CREF Investment Management LLC now owns 398,366 shares of the company’s stock valued at $11,218,000 after buying an additional 124,066 shares in the last quarter. Teachers Advisors Inc. boosted its position in shares of Astrazeneca PLC by 595.6% in the first quarter. Teachers Advisors Inc. now owns 510,989 shares of the company’s stock valued at $14,389,000 after buying an additional 437,531 shares in the last quarter. Franklin Resources Inc. boosted its stake in Astrazeneca PLC by 89.8% in the first quarter. Franklin Resources Inc. now owns 2,026,200 shares of the company’s stock valued at $57,058,000 after buying an additional 958,821 shares during the period. BlackRock Institutional Trust Company N.A. boosted its stake in Astrazeneca PLC by 118.1% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 11,230 shares of the company’s stock valued at $316,000 after buying an additional 6,081 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in Astrazeneca PLC by 0.3% in the first quarter. JPMorgan Chase & Co. now owns 2,325,462 shares of the company’s stock valued at $65,485,000 after buying an additional 6,027 shares during the period. 11.39% of the stock is owned by institutional investors.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.